The data are consistent with our recent studies showing that knockdown of Lgmn in macrophages extended the survival of CT2A tumor–bearing mice (37), and this extension was abolished by the treatment with Colivelin (Figure 2H). This evidence concerns the gene LGMN and neoplasm.